CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Individualizing Therapeutic Decisions to Improve Patient Outcomes

Learn how global experts are leveraging the latest data on CDK4/6 inhibitors in patients with HR+/HER2- EBC. Watch the on-demand webcast from the live webinar download the slides and listen to the podcast featuring expert reviews of the most important data on early breast cancer from ESMO Breast 2021.

Share

Program Content

No activities added yet

Activities

HR+/HER2- EBC Slides
Individualizing Therapeutic Decision-Making for Patients With HR+/HER2- EBC: Downloadable Slides
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 12, 2021

Adj HR+/HER2- EBC Slides
Adjuvant Therapy for Patients With HR+/HER2- EBC at High Risk of Recurrence: Downloadable Slides
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 12, 2021

NeoAdj HR+/HER2- EBC Slides
Debating Optimal Neoadjuvant Therapy and Future Considerations on the Horizon for HR+/HER2- EBC: Downloadable Slides
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 12, 2021

Update: Treatment of HR+/HER2- EBC
Update: Individualizing Therapeutic Decision-Making for Patients With HR+/HER2- EBC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 02, 2021

Expires: July 01, 2022

Update: Adj Tx of HR+/HER2- EBC
Update: Adjuvant Therapy for Patients With HR+/HER2- EBC at High Risk of Recurrence
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 02, 2021

Expires: July 01, 2022

Update: NeoAdj Tx of HR+/HER2- EBC
Update: Debating Optimal Neoadjuvant Therapy and Future Considerations on the Horizon for HR+/HER2- EBC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 02, 2021

<i>EP</i>: CDK4/6i in EBC
ExpressPoints
CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Individualizing Therapeutic Decisions to Improve Patient Outcomes
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 09, 2021

Activities

Q&A: CDK4/6i in Early BC
CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Expert Answers to Clinician Questions
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: August 05, 2021

Expires: August 04, 2022

Podcast Pearls: CDK4/6i in EBC
CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Podcast Pearls
PDF
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: August 17, 2021

Expires: August 16, 2022

Faculty

cover img faculity

Javier Cortes, MD, PhD

Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain

cover img faculity

Stephen R. D. Johnston, MA, FRCP, PhD

Professor of Breast Cancer Medicine
Breast Unit
Department of Medicine
Royal Marsden Hospital
London, United Kingdom

cover img faculity

Stephen Raffanti, MD, MPH

Associate Professor of Medicine
Division of Infectious Disease
Vanderbilt University School of Medicine
Chief Medical Officer
Comprehensive Care Center
Nashville, Tennessee

cover img faculity

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Lilly